HSA-Free Interferon Beta Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interferon-beta pharmaceutical formulations rely on human serum albumin (HSA) for solubility enhancement, which poses risks due to potential human virus transmission and instability issues, necessitating HSA-free compositions that stabilize interferon-beta and improve solubility.
Innovation Solution
Development of HSA-free pharmaceutical compositions comprising interferon-beta with a buffer, an amino acid, and an antioxidant, along with a bacteriostatic agent, to enhance stability and solubility, and potentially include muteins, fused proteins, or consensus interferons, which are formulated with surfactants like Pluronic F68 to prevent aggregation and oxidation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If human serum albumin (HSA) is used to enhance solubility of interferon-beta, then solubility is improved, but risk of viral transmission and instability increases
Solution Approach 1:
The invention removes HSA from the formulation completely, extracting the problematic component while maintaining solubility enhancement through alternative means (amino acids and surfactants). This resolves the contradiction by eliminating the safety risk while preserving the solubility benefit through different mechanisms.
Solution Approach 2:
The invention replaces the expensive and risky HSA with simpler, safer components (amino acids like lysine or arginine, and surfactants like Pluronic F68) that can be synthesized or produced without viral contamination risks. These alternative components achieve the same solubility enhancement function without the safety drawbacks.
2Reliability
If interferon-beta is formulated without HSA, then safety is improved, but solubility and stability deteriorate
Solution Approach 1:
The invention creates a composite formulation system combining multiple components (buffer, amino acid, antioxidant, surfactant) that work synergistically to maintain interferon-beta solubility and stability without HSA. The amino acid prevents aggregation while the surfactant enhances solubility, and the antioxidant prevents oxidation, collectively replacing HSA's multiple functions.
Solution Approach 2:
The invention optimizes specific parameters including pH (adjusted via buffer to 3.5-5.5), ionic strength, and component concentrations to achieve stable solubility without HSA. By carefully controlling these physical-chemical parameters, the formulation maintains interferon-beta in a stable, soluble state through alternative mechanisms.
3Stability of the object's composition
If interferon-beta formulations include stabilizing agents, then stability is improved, but formulation complexity increases
Solution Approach 1:
The invention selects components that perform multiple functions: amino acids provide both solubility enhancement and aggregation prevention, while surfactants like Pluronic F68 provide solubility enhancement and also protect against surface adsorption. This multi-functionality reduces the need for additional specialized stabilizers, managing complexity while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain at least 60% biological activity over 12-24 months, offering a stable and safe alternative with extended shelf-life and reduced risk of viral transmission, while minimizing protein loss and oxidation, thus enhancing pharmaceutical utility.
Implementation Method 1
an antioxidant... to enhance stability and solubility, and potentially include muteins, fused proteins, or consensus interferons, which are formulated with surfactants like Pluronic F68 to prevent aggregation and oxidation
Implementation Method 2
formulated with surfactants like Pluronic F68 to prevent aggregation and oxidation
Data Source
AI summary
A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, an amino acid and an antioxidant. Preferably, the interferon is human recombinant IFN-beta.